(Q37828163)

23 August 2017

1 reference

title

Novel γ-secretase modulators: a review of patents from 2008 to 2010. (English)

1 reference

23 August 2017

0 references

Martin Pettersson

1

1 reference

23 August 2017

Gregory W Kauffman

2

1 reference

23 August 2017

Christopher W am Ende

3

1 reference

23 August 2017

Nandini C Patel

4

1 reference

23 August 2017

Cory Stiff

5

1 reference

23 August 2017

Tuan P Tran

6

1 reference

23 August 2017

Douglas S Johnson

7

1 reference

23 August 2017

language of work or name

English

0 references

publication date

14 January 2011

1 reference

Expert Opinion on Therapeutic Patents

23 August 2017

published in

1 reference

23 August 2017

volume

21

1 reference

23 August 2017

issue

2

1 reference

23 August 2017

page(s)

205-226

1 reference

gamma-secretases: from cell biology to therapeutic strategies

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

Presenilin: running with scissors in the membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

The gamma-secretase complex: membrane-embedded proteolytic ensemble

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

Substrate specificity of gamma-secretase and other intramembrane proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

The genetics of Alzheimer disease: back to the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

Alzheimer's failure raises questions about disease-modifying strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

Notch signalling in vertebrate neural development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

Why did tarenflurbil fail in Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

Exploring the chemical space of gamma-secretase modulators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

Substrate-targeting gamma-secretase modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

Nonspecificity of binding of gamma-secretase modulators to the amyloid precursor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

Beta-amyloid precursor protein mutants respond to gamma-secretase modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

Secretion of the Notch-1 Abeta-like peptide during Notch signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

Amyloid beta 42 peptide (Abeta42)-lowering compounds directly bind to Abeta and interfere with amyloid precursor protein (APP) transmembrane dimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

Substrate docking to γ-secretase allows access of γ-secretase modulators to an allosteric site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

Piperidine-derived gamma-secretase modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

Therapeutic potential of gamma-secretase inhibitors and modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

Iminoheterocycles as gamma-secretase modulators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I--inhibitor design and validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

The Discovery of Pyridone and Pyridazone Heterocycles as γ-Secretase Modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

Piperazinyl pyrimidine derivatives as potent gamma-secretase modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

Purine derivatives as potent gamma-secretase modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

Physiochemical drug properties associated with in vivo toxicological outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.547479

10.1517/13543776.2011.547479

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference